Discovery, development, and large-scale production of protein

LenioBio closes Series-A Extension round

09-Mar-2022 - Germany

LenioBio GmbH, a German life sciences biotech offering a disruptive protein manufacturing technology, ALiCE®, closed its Series-A Extension round with a total investment volume of €11.5 million. The investment round, which was closed in November 2021, is led by LenioBio's current investor Bridford Group, a PE investor focusing on founder-led businesses with long-term growth potential and concerned with societal or environmental welfare. 

pixabay.com

Symbolic image

The raised funds will be used to accelerate LenioBio’s continuous efforts in research and development of the ALiCE technology, process improvement of large-scale manufacturing and mapping of the various market opportunities.

“After we reached our first milestones in scaling the technology, the Series-A Extension round will now enable us to achieve the next infliction points on our way to establish our disruptive technology on the market” said Franziska Finke, CFO at LenioBio.

Along with the investment round, LenioBio strengthens its Non-executive Board of Directors. New Board members include Dr. Remberto Martis, founder and CEO, Thomas Harding, Leopoldo Zambeletti and Karen Fallen.

Thomas Harding is a partner at Bridford Group and a director of several portfolio companies, such as Hudson River Biotechnology and Touchlight Holdings Limited. He previously worked on TMT investments at Access Industries, after joining from Weil, Gotshal and Manges’ private equity department and has been active in several other director and officer positions. He has a MA from the University of Cambridge and subsequently studied at City University (law) and London Business School (finance).

Karen Fallen is currently the CEO of Touchlight DNA Services and has extensive experience in the Biopharma industry. Having worked for Lonza for 14 years, she held various leading positions in clinical development and manufacturing as well as in licensing and business development. She received her degree in Applied Biology, Industrial Biology, Immunology and Biotechnology from the Thames Valley University.

Leopoldo Zambeletti started his career as an auditor at KPMG and has more than 19 years' experience as investment banker, i.e. leading the European Healthcare Investment Banking team at JP Morgan and at Credit Suisse. As independent strategic consultant to life science companies he is since 2013 advising companies on financial deals, out-licensing, and M&A. He graduated as BA in Business at the Bocconi University in Milan, Italy.

“Our new Board members bring extensive experience in different fields of the business. Their input will be crucial in setting the mid- and long-term strategy of the company which will now focus on the validation of the ALiCE technology. With the new Board composition, LenioBio is well positioned to achieve the next stage on our journey.” said Dr. Remberto Martis, CEO of LenioBio.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Something is happening in the life science industry ...

This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.

See the theme worlds for related content

Topic world biopharmaceutical manufacturing

Biopharmaceutical production plays a crucial role in the development and manufacture of biologics, which are essential for the treatment of various serious diseases. Various key technologies and processes of the modern biopharmaceutical industry are used, such as cell cultures, fermentation processes and the purification of biological substances, which are necessary for the production of vaccines, monoclonal antibodies and other biological drugs.

20+ products
15+ brochures
View topic world

Topic world biopharmaceutical manufacturing

Biopharmaceutical production plays a crucial role in the development and manufacture of biologics, which are essential for the treatment of various serious diseases. Various key technologies and processes of the modern biopharmaceutical industry are used, such as cell cultures, fermentation processes and the purification of biological substances, which are necessary for the production of vaccines, monoclonal antibodies and other biological drugs.

20+ products
15+ brochures